Ultragenyx Pharmaceutical heads into the post-earnings week with short sellers adding positions and analysts pulling in opposite directions — a split that reflects the market's unresolved read on whether the Q1 revenue miss is seasonal noise or something more worrying.
Short interest is rising meaningfully, and has been for a month. SI as a percentage of the free float climbed to roughly 12.9% by May 5, up from around 10.2% in early April — a 20% increase over the past month. The weekly change was just under 2%, but the trajectory is consistent and pointed: shorts have been building steadily since early April, adding approximately two million shares since the start of that month. At 7.1 days to cover per the most recent FINRA filing, an unwind of those positions is not trivial. That said, the borrow market itself is not showing stress. Cost to borrow is just 0.46%, well below what would signal a tight squeeze environment, and availability remains ample — the lending pool is wide open relative to the shares already borrowed. The short-score, at 54.6, sits in mid-range territory; not extreme, but edging higher across the past two weeks.
Options traders, by contrast, have turned less defensive since the report. The put/call ratio eased to 0.74, a touch below its 20-day average of 0.76 and close to a one-standard-deviation underrun of recent norms. That is a mild tilt toward calls, suggesting options participants are not rushing to hedge aggressively. The PCR has fallen steadily since early April, when it ran north of 0.81 amid broader market anxiety, back to more neutral ground. The configuration — shorts rebuilding while options skew mildly bullish — is a genuine divergence worth noting.
On the Street, the post-earnings verdict is divided, and the math is stark. Wells Fargo, maintaining Overweight, nudged its target up to $47 on May 6. Wedbush went the other direction, trimming its Neutral target to $26, barely above the current $25.01 close. Barclays kept its Overweight but trimmed to $43 ahead of earnings. The consensus mean target is $53.20 — roughly double today's price — but that aggregate is heavily influenced by Morgan Stanley's $67 target (raised from $50 in April) and JPMorgan's $74. Goldman, which downgraded to Neutral from Buy in late March with a $25 target, is the most bearish of the major houses and is essentially flagging that the stock is now fairly valued. The wide dispersion in targets reflects genuine uncertainty: Q1 revenue came in at $136 million, down year-on-year from $139 million, with a loss per share of $1.84 widening from $1.57. Management reaffirmed full-year guidance of around $733-$743 million, but that was already below prior consensus of ~$785 million. The bull case rests on Crysvita's trajectory and the coming PDUFA dates for DTX401 (August 23) and UX111; the bear case is that the revenue guidance cut raises doubts about execution, with GAAP profitability still targeted for 2027 — a year away and contingent on pipeline success.
The factor picture is mixed but includes some genuinely constructive signals. The 12-month forward EPS estimate trend ranks in the 95th percentile — meaning the earnings revision trajectory, whatever it says on an absolute basis, is improving sharply relative to peers. The 30-day EPS momentum score also ranks in the 86th percentile. EPS surprise history ranks 78th. These are not the readings of a company missing expectations chronically; they point to a bar that has been reset lower but is now being cleared. The utilization rank of 70 reflects a moderately elevated lending profile but not a crowded short trade.
The one area where caution is warranted is the historical earnings reaction. The only prior quarter with usable price-reaction data is Q4 2025 (reported February 12, 2026), which saw the stock fall 14.1% on the day. The Q1 2026 result on May 5 produced a much smaller reaction — the stock is up around 1% this week — suggesting the bar had already been reset and the quarter was broadly within expectations despite the headline miss. The next formal earnings event is flagged for around August 3, coinciding with the DTX401 PDUFA date of August 23.
The next catalyst is therefore less about quarterly numbers and more about whether the FDA review of DTX401 and UX111 proceeds on schedule — two gene therapy approvals in the same year would materially change the revenue story that analysts are currently discounting at a wide range of assumptions.
See the live data behind this article on ORTEX.
Open RARE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
